Edwards Lifesciences

Shares of Edwards Lifesciences rose to a 52-week high of 92.94 USD and are currently trading just below that level; year-to-date the stock is up about 20.09%. The company trades at a P/E ratio of 50.01 and is considered overvalued by InvestingPro. At the New York Valves 2026 conference Edwards presented data from the PROGRESS study on TAVR, and the U.S. government proposed a National Coverage Decision memorandum for TAVR, which analysts view positively. Leerink reiterated "Market Perform" with a price target of 87 USD, TD Cowen raised its target to 104 USD; Theodora Mistras was also appointed as the new chief financial officer. » Más en de.investing.com

Edwards Lifesciences shares rose to a 52-week high of $87.89 and are currently trading at $87.91. In Q1 2026 the company reported revenue of $1.65bn (+12.7% currency‑adjusted) and earnings per share of $0.78, both above expectations. Analysts revised their views: several firms raised price targets and ratings, while InvestingPro rates the stock as overvalued and several earnings forecasts were revised down. Theodora Mistras was also appointed as the new chief financial officer effective late May. » Más en de.investing.com

Edwards Lifesciences has appointed Doretta Mistras as corporate vice president and CFO; she will assume the role at the end of May and succeeds Scott Ullem, who had already announced his departure and will remain as a strategic adviser during the transition. Mistras joins from Viatris, where she had served since March 2024 as CFO of the global finance organization and previously held leadership roles in healthcare investment banking at Citigroup and Goldman Sachs. The company has a market capitalization of $48 billion, revenue growth of 14% and a gross profit margin of nearly 78%; the stock is trading near its 52-week high. Analysts have recently cut their earnings forecasts (13 analysts), giving the CFO change added significance. » Más en de.investing.com